Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma

Pottegård, Anton; Pedersen, Sidsel Arnspang; Schmidt, Sigrún Alba Jóhannesdóttir; Hølmich, Lisbet Rosenkrantz; Friis, Søren; Garcı́a-Dorado, David

doi:10.1001/jamainternmed.2018.1652

Cited by 83 publications

(109 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whether the same level of risk exists in other populations needs to be investigated. In a second analysis using the same databases, the same authors reported an increase in the risk of nodular melanoma with the use of HCTZ [17]. The risks of both BCC and nodular melanoma were relatively low.…”

Section: Editorialmentioning

confidence: 88%

New data on antihypertensive drugs and risk of cancer: should we worry?

2019

View full text Add to dashboard Cite

Section: Editorialmentioning

confidence: 88%

New data on antihypertensive drugs and risk of cancer: should we worry?

2019

View full text Add to dashboard Cite

“…Additionally, amiloride and spironolactone are notorious for the potential to cause gynecomastia in males [80], which may have a psychosocial impact in an adolescent and contribute to non-compliance; thus, eplerenone would be the preferred option in these patients. Lastly, Pederson et al and Pottergard et al recently reported an association between hydrochlorothiazide and risk of Merkel cell carcinoma, malignant adnexal skin tumors, and other nonmelanoma skin cancers, respectively [81][82][83][84]. Although these findings have not been corroborated by other authors [83], given that hydrochlorothiazide is a known photosensitizer, routine sun protection should be emphasized in patients.…”

Section: Safetymentioning

confidence: 90%

Antihypertensive agents: a long way to safe drug prescribing in children

Siddiqi

Shatat

2019

Pediatr Nephrol

View full text Add to dashboard Cite

Recently updated clinical guidelines have highlighted the gaps in our understanding and management of pediatric hypertension. With increased recognition and diagnosis of pediatric hypertension, the use of antihypertensive agents is also likely to increase. Drug selection to treat hypertension in the pediatric patient population remains challenging. This is primarily due to a lack of large, well-designed pediatric safety and efficacy trials, limited understanding of pharmacokinetics in children, and unknown risk of prolonged exposure to antihypertensive therapies. With newer legislation providing financial incentives for conducting clinical trials in children, along with publication of pediatric-focused guidelines, literature available for antihypertensive agents in pediatrics has increased over the last 20 years. The objective of this article is to review the literature for safety and efficacy of commonly prescribed antihypertensive agents in pediatrics. Thus far, the most data to support use in children was found for angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), and calcium channel blockers (CCB). Several gaps were noted in the literature, particularly for beta blockers, vasodilators, and the long-term safety profile of antihypertensive agents in children. Further clinical trials are needed to guide safe and effective prescribing in the pediatric population.

show abstract

“…Taking the current uncertainties regarding the prescription of HCT [30,31] into account we considered thiazides more precisely and find a 0.07 % increase in HbA1c while a higher dose of 25 mg HCT is used compared to 12.5 mg. This might be caused by an inhibition of the insulin release from the pancreas due to the effect of thiazides.…”

Section: Discussionmentioning

confidence: 99%

Association Between Glycaemic Control and the Intake of Thiazide Diuretics, Beta Blockers and Levothyroxine in People Without Diabetes

Roth

Müller

Kuniß

et al. 2019

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Objective The pharmacological additional information for many medications includes warnings stating that the blood sugar control may be worsened by the intake of certain drugs. However a quantification of the effects is missing. This may result in confusion for patients as well as for their physicians. The aim of this study was to assess a potential association between medication (beta blockers, thiazides, levothyroxine) and HbA1c in people without diabetes. Methods In this cross-sectional study we analysed data from 2 921 people (7 699 visits) without diabetes (age 46.6 y; 69.1% women; BMI 27.6±6.4 kg/m²; HbA1c 5.2%) who had at least one HbA1c determination and a complete documentation of their drug intake. An oral glucose tolerance test was not performed. The participants were divided in 8 groups (no regular drug intake, levothyroxine alone, beta blockers alone, thiazides alone, combination 2 of 3, combination of all 3). Patients with known distorting influences of the HbA1c were excluded. Results People with no regular drug intake had an HbA1c of 5.4% [35.8 mmol/mol]. The HbA1c of the group that took all 3 drugs in combination was 5.6% [38.2 mmol/mol]. A multiple linear mixed model showed an increase in HbA1c for thiazides (β=0.0558, p=0.025) and a decrease for combination of levothyroxine and thiazide (β=−0.0765, p=0.010). Conclusion Thiazides and the combination of levothyroxine and thiazides were associated with slight changes in HbA1c. In this study there was no association between the intake of beta blockers and HbA1c. At least for people without diabetes these effects seem to be of minor importance.

show abstract

Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma

Abstract: This case-control study assesses the association of hydrochlorothiazide with risk of malignant melanoma among Danish adults.

Cited by 83 publications

References 9 publications

New data on antihypertensive drugs and risk of cancer: should we worry?

New data on antihypertensive drugs and risk of cancer: should we worry?

Antihypertensive agents: a long way to safe drug prescribing in children

Association Between Glycaemic Control and the Intake of Thiazide Diuretics, Beta Blockers and Levothyroxine in People Without Diabetes

Contact Info

Product

Resources

About